#301 - AMA #59: Inflammation: its impact on aging and disease risk, and how to identify, prevent, and reduce it

May 13, 2024 Episode Page ↗
Overview

Peter Attia, MD, and Nick Stenson discuss inflammation, defining acute vs. chronic forms and its link to aging, disease, and metabolic health. The episode sets the stage for future discussion on managing chronic inflammation through diet, exercise, sleep, and stress.

At a Glance
4 Insights
24m 18s Duration
7 Topics
6 Concepts

Deep Dive Analysis

Introduction to Inflammation and its Misconceptions

Defining Inflammation: Biological Response and Purpose

Distinguishing Acute vs. Chronic Inflammation

The Connection Between Chronic Inflammation, Aging, and Disease

Causality of Inflammation and Disease: The Cantos Trial

Inflammation's Relationship with Obesity and Metabolic Health

Understanding and Diagnosing Chronic Inflammation

Inflammation

Inflammation is a biological response of the immune system designed to defend against harmful stimuli and eliminate the cause of injury. While often essential for tissue repair and clearing pathogens, it can become maladaptive if prolonged.

Acute Inflammation

This is the immediate, short-term response to injury or infection, characterized by physical signs like warmth, pain, swelling, and potential loss of function. It is a crucial part of the body's healing process.

Chronic Inflammation

This type of inflammation persists for months to years, often without the obvious physical signs of acute inflammation, making it 'low-grade' and frequently asymptomatic. It is considered maladaptive and linked to various diseases and aging.

Hallmarks of Aging

These are cellular mechanisms that occur as we age, such as decreased nutrient sensing, cellular senescence, genomic instability, and epigenetic changes. Low-grade inflammation is recognized as one of these hallmarks, contributing to the aging process.

Four Horsemen

This term refers to the major age-related diseases: atherosclerotic diseases, cancer, neurodegenerative diseases, and metabolic diseases. Chronic inflammation shows an incredibly high association with these conditions, suggesting a causal link.

Ectopic and Visceral Fat

These refer to fat stored around organs and within tissues other than under the skin (subcutaneous fat). Ectopic and visceral fat are strongly associated with promoting inflammation and chronic disease, more so than subcutaneous fat.

?
What is inflammation?

Inflammation is the immune system's biological response to defend against harmful stimuli and eliminate the cause of injury, playing a crucial role in healing and clearing pathogens.

?
What is the difference between acute and chronic inflammation?

Acute inflammation is a short-term, immediate response with obvious signs like redness and swelling, essential for healing. Chronic inflammation persists for months or years, often low-grade and asymptomatic, and is considered maladaptive.

?
How is chronic inflammation connected to aging and age-related diseases?

Chronic inflammation is recognized as one of the hallmarks of aging and is strongly associated with the 'Four Horsemen' (atherosclerotic diseases, cancer, neurodegenerative diseases, and metabolic diseases), suggesting a causal link to increased mortality and disease risk.

?
Does inflammation cause disease, or is it just associated with it?

While epidemiological studies show strong associations, trials like the Cantos trial, which targeted inflammation and reduced major adverse cardiac events, bolster the claim that high inflammation plays a causal role in disease.

?
How does inflammation relate to obesity and metabolic health?

There's a clear relationship between inflammation and excess adiposity, particularly ectopic and visceral fat (fat around organs), which promote far more inflammation than subcutaneous fat. This explains the strong association between obesity and chronic disease.

1. Prioritize Holistic Inflammation Reduction

When addressing chronic inflammation, favor holistic approaches over pharmacologic interventions that target isolated pathways, as these broader methods are likely a better and safer way to reduce inflammation.

2. Minimize Visceral Fat

Focus on reducing visceral and ectopic fat, as these internal fat stores, rather than subcutaneous fat, are the primary drivers of the chronic inflammatory response that should be avoided.

3. Cautious Inflammation Targeting

Be very careful when targeting inflammation, especially with specific drugs, as demonstrated by trials where reducing inflammation in one pathway led to increased risk of serious infections.

4. Reduce Inflammation, Lower Disease Risk

Understand that high chronic inflammation is believed to play a causal role in age-related diseases, and actively reducing it can therefore decrease the risk of conditions like cancer and cardiovascular mortality.

Inflammation is a biological response of the immune system to defend against some sort of stimulus, usually harmful, but not always, and to eliminate the cause of injury.

Peter Attia

It's when inflammation becomes more chronic, even after the acute problem has resolved, or sometimes when it lingers, that it becomes maladaptive and the balance tips against the organism or the host, which is us.

Peter Attia

If you believe, as I do, that high inflammation plays a causal role in these diseases, then reducing inflammation should therefore reduce the risk of those things.

Peter Attia

Be very careful of how you target inflammation. And holistic, as much as I hate that word, holistic ways to target inflammation, which is really what we're going to talk about in this podcast, are probably the better way to go as opposed to pharmacologic hammers that really get at, in this case, one kind of isolated pathway.

Peter Attia
2.71
Hazard ratio for all-cause mortality with high C-reactive protein (CRP > 10 mg/L) Indicates a 171% increased risk of death from any cause relative to someone with low CRP, based on an observational study of 160,000 participants.
3.16
Hazard ratio for cancer mortality with high C-reactive protein (CRP > 10 mg/L) Based on an observational study of 160,000 participants.
2.33
Hazard ratio for cardiovascular mortality with high C-reactive protein (CRP > 10 mg/L) Based on an observational study of 160,000 participants.
2.17
Hazard ratio for cerebrovascular mortality with high C-reactive protein (CRP > 10 mg/L) Based on an observational study of 160,000 participants.
10,000
Number of patients in the Cantos trial Patients with significant ASCVD (previously suffered heart attacks) and HSCRP above 2 mg/L.
above 2 milligrams per liter
HSCRP level for patients in the Cantos trial Normal HSCRP is typically below 1 mg/L.
every three months
Treatment frequency in the Cantos trial Patients were treated with a monoclonal antibody against interleukin-1-beta or placebo.
about four years
Treatment duration in the Cantos trial Median follow-up was just under four years.
15%
Relative reduction in Major Adverse Cardiac Events (MACE) in the Cantos trial Observed in the two higher dose groups of the anti-inflammatory antibody.